<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="pmc-domain-id">440</journal-id><journal-id journal-id-type="pmc-domain">plosone</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>PLOS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11108141</article-id><article-id pub-id-type="pmcid-ver">PMC11108141.1</article-id><article-id pub-id-type="pmcaid">11108141</article-id><article-id pub-id-type="pmcaiid">11108141</article-id><article-id pub-id-type="pmid">38771740</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0298612</article-id><article-id pub-id-type="publisher-id">PONE-D-23-00257</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Addicts</subject><subj-group><subject>Alcoholics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Addicts</subject><subj-group><subject>Alcoholics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Alcoholism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Alcoholism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Mental Health and Psychiatry</subject><subj-group><subject>Substance-Related Disorders</subject><subj-group><subject>Alcoholism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Substance-Related Disorders</subject><subj-group><subject>Alcoholism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Bacterial Diseases</subject><subj-group><subject>Bacteremia</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Nosocomial Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Health Care</subject><subj-group><subject>Health Care Facilities</subject><subj-group><subject>Hospitals</subject><subj-group><subject>Intensive Care Units</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus Aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus Aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus Aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Prognosis</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title><italic toggle="yes">Staphylococcus aureus</italic> bacteremia in alcoholics</article-title><alt-title alt-title-type="running-head">Staphylococcus aureus bacteremia in alcoholics</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9891-1256</contrib-id><name name-style="western"><surname>Kessel</surname><given-names initials="K">Klaus</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="cor001" ref-type="corresp">*</xref><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Forsblom</surname><given-names initials="E">Erik</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ruotsalainen</surname><given-names initials="E">Eeva</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>J&#228;rvinen</surname><given-names initials="A">Asko</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff"/></contrib></contrib-group><aff id="aff001">
<addr-line>Division of Infectious Diseases, Inflammation Center, Helsinki University Hospital, Helsinki, Finland</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Amponsah</surname><given-names initials="OKO">Obed Kwabena Offe</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Kwame Nkrumah University of Science and Technology Faculty of Pharmacy and Pharmaceutical Sciences, GHANA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>AJ has received speaker honoraria from Astellas, Gilead and MSD and compensation from consultation from AstraZeneca, Biomerieux, GSK, MSD and Nordisk Infucare and grant for congress attendance from Octapharma, all outside the scope of the present study. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p></fn><corresp id="cor001">* E-mail: <email>klaus.kessel@hus.fi</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>5</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>19</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">461463</issue-id><elocation-id>e0298612</elocation-id><history><date date-type="received"><day>4</day><month>1</month><year>2023</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>21</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-22 11:25:14.323"><day>22</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 Kessel et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Kessel et al</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pone.0298612.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="pone.0298612.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Alcoholism associates with increased <italic toggle="yes">Staphylococcus aureus</italic> bacteremia incidence and mortality. The objective was to compare disease progression, treatment and prognosis of <italic toggle="yes">Staphylococcus aureus</italic> bacteremia in alcoholics versus non-alcoholics.</p></sec><sec id="sec002"><title>Methods</title><p>The study design was a multicenter retrospective analysis of methicillin-sensitive <italic toggle="yes">Staphylococcus aureus</italic> bacteremia with 90-day follow-up. Patients were stratified as alcoholics or non-alcoholics based on electronic health record data. Altogether 617 <italic toggle="yes">Staphylococcus aureus</italic> bacteremia patients were included of which 83 (13%) were alcoholics.</p></sec><sec id="sec003"><title>Results</title><p>Alcoholics, versus non-alcoholics, were younger, typically male and more commonly had community-acquired <italic toggle="yes">Staphylococcus aureus</italic> bacteremia. No differences in McCabe&#180;s classification of underlying conditions was observed. Higher illness severity at blood culture sampling, including severe sepsis (25% vs. 7%) and intensive care unit admission (39% vs. 17%), was seen in alcoholics versus non-alcoholics. Clinical management, including infectious disease specialist (IDS) consultations and radiology, were provided equally. Alcoholics, versus non-alcoholics, had more pneumonia (49% vs. 35%) and fewer cases of endocarditis (7% vs. 16%). Mortality in alcoholics versus non-alcoholics was significantly higher at 14, 28 and 90 days (14% vs. 7%, 24% vs. 11% and 31% vs. 17%), respectively. Considering all prognostic parameters, male sex (OR 0.19, p = 0.021) and formal IDS consultation (OR 0.19, p = 0.029) were independent predictors of reduced mortality, whereas ultimately or rapidly fatal comorbidity in McCabe&#180;s classification (OR 12.34, p &lt; 0.001) was an independent predictor of mortality in alcoholics.</p></sec><sec id="sec004"><title>Conclusions</title><p>Alcoholism deteriorates <italic toggle="yes">Staphylococcus aureus</italic> bacteremia prognosis, and our results suggests that this is predominantly through illness severity at bacteremia onset. Three quarters of <italic toggle="yes">Staphylococcus aureus</italic> bacteremia patients we studied had identified deep infection foci, and of them alcoholics had significantly less endocarditis but nearly half of them had pneumonia.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100008376</institution-id><institution>Helsingin ja Uudenmaan Sairaanhoitopiiri</institution></institution-wrap></funding-source></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100010135</institution-id><institution>Finska L&#228;kares&#228;llskapet</institution></institution-wrap></funding-source><principal-award-recipient><name name-style="western"><surname>Forsblom</surname><given-names>Erik</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100010119</institution-id><institution>Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perkl&#233;ns Minne</institution></institution-wrap></funding-source><principal-award-recipient><name name-style="western"><surname>Forsblom</surname><given-names>Erik</given-names></name></principal-award-recipient></award-group><funding-statement>The study was supported by grants from the Hospital District of Helsinki and Uusimaa. AJ has received speaker honoraria from Astellas, Gilead and MSD and compensation from consultation from AstraZeneca, Biomerieux, GSK, MSD and Nordisk Infucare and grant for congress attendance from Octapharma, all outside the scope of the present study. EF has received personal grants from 1) The Medical Society of Finland. 2) The Perkl&#233;ns Foundation abd 3) The Liv and H&#228;lsa foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="5"/><page-count count="13"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its <xref rid="sec022" ref-type="sec">Supporting Information</xref> files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its <xref rid="sec022" ref-type="sec">Supporting Information</xref> files.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Alcohol use disorders and alcoholism affects 283 million people worldwide [<xref rid="pone.0298612.ref001" ref-type="bibr">1</xref>]. Alcoholism increases the occurrence of various infectious diseases such as bacterial pneumonia and blood culture-positive infections. Furthermore, alcoholism deteriorates prognosis and increases mortality in bacterial pneumonia and blood culture-positive infections [<xref rid="pone.0298612.ref002" ref-type="bibr">2</xref>&#8211;<xref rid="pone.0298612.ref005" ref-type="bibr">5</xref>]. The connection between alcoholism and increased risk and severity of infections is presented as multifactorial [<xref rid="pone.0298612.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0298612.ref006" ref-type="bibr">6</xref>]. Previous studies suggests that alcohol impairs the immune system through cellular and molecular modifications, including macrophage and neutrophil disturbance, lung surfactant and ciliary dysfunction [<xref rid="pone.0298612.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0298612.ref007" ref-type="bibr">7</xref>]. Studies associate alcohol abuse with malnutrition, poor dental hygiene and increased aspiration risk through blunted cough reflexes&#8211;factors lowering the threshold for infections [<xref rid="pone.0298612.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0298612.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0298612.ref008" ref-type="bibr">8</xref>]. Alcoholism has been hypothesized to create a state of subclinical immunocompromise, increasing the risk for severe invasive infections [<xref rid="pone.0298612.ref008" ref-type="bibr">8</xref>].</p><p><italic toggle="yes">Staphylococcus aureus</italic> causes severe bacteremia (SAB) and is associated with significant morbidity and mortality [<xref rid="pone.0298612.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0298612.ref010" ref-type="bibr">10</xref>]. The incidence of SAB is high in alcoholics [<xref rid="pone.0298612.ref004" ref-type="bibr">4</xref>] and alcoholism is a common comorbidity among SAB patients, with reports of up to 14% of SAB patients suffering from alcoholism [<xref rid="pone.0298612.ref011" ref-type="bibr">11</xref>&#8211;<xref rid="pone.0298612.ref014" ref-type="bibr">14</xref>]. Several reports demonstrate that alcoholism is an independent predictor of mortality in SAB [<xref rid="pone.0298612.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0298612.ref015" ref-type="bibr">15</xref>]. Disease progression and prognosis in SAB are impacted by age and comorbidities [<xref rid="pone.0298612.ref016" ref-type="bibr">16</xref>], the severity of illness [<xref rid="pone.0298612.ref017" ref-type="bibr">17</xref>], deep infection foci, e.g., endocarditis [<xref rid="pone.0298612.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0298612.ref019" ref-type="bibr">19</xref>]. Appropriate clinical management and infectious disease specialist (IDS) consultation [<xref rid="pone.0298612.ref020" ref-type="bibr">20</xref>] may improve outcomes. Formal IDS consultation has been suggested as a mandatory part of SAB management [<xref rid="pone.0298612.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0298612.ref022" ref-type="bibr">22</xref>]. However, despite knowledge that alcoholism is a risk factor for acquiring SAB, alcoholism is common among SAB patients and alcoholism deteriorates prognosis in SAB, there is no data on how the disease among alcoholics differs from non-alcoholics.</p><p>The objective of our study was to explore the disease progression, treatment and prognosis of methicillin-sensitive (MS) SAB in alcoholics compared to non-alcoholics and to evaluate whether alcoholism would serve as a marker for risk stratification of <italic toggle="yes">Staphylococcus aureus</italic> bacteremia patients. The study was conducted in a low-resistance area and the inclusion of only MS-SAB enabled each patient to receive appropriate antimicrobial therapy without differences in empirical antibiotic choice.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Materials and methods</title><sec id="sec007"><title>Study population</title><p>This was a multicenter retrospective cohort study with 90 days of follow-up, including all adult patients with at least one blood culture positive for MS-SAB from five university and seven central hospitals in Finland during January&#8211;May 1999 and January 2000 &#8211;August 2002. Furthermore, as an extension, each adult patient with positive blood culture for MS-SAB from Helsinki University Hospital in Finland from January 2006 &#8211;December 2007 was included. Patient data was retrieved from both written (years 1999&#8211;2002) and electronic (years 2006&#8211;2007) hospital archives. We decided to include two time periods to exclude any unknown temporary differences in personnel arrangements or treatment practices. Any possible disadvantage with either information storage pattern was accounted for by including both paper and electronic hospital records. Patients and corresponding <italic toggle="yes">Staphylococcus aureus</italic> bacterial isolates were matched through the unique personal number provided to all Finnish residents. A total of five cases of methicillin-resistant SAB were excluded. Data collection included gender, age, bacteremia acquisition, underlying diseases, length and administration route of any antibiotic therapy. Any pre-bacteremia abuse of alcohol was documented. Infection focus documentation was based on either clinical suspicion only or verified by radiological, bacteriological, or pathological investigations. Laboratory results and time to defervescence (axillary temperature &lt; 37.5&#176;C) and hospital and ICU (intensive care unit) duration were recorded.</p><sec id="sec008"><title>Ethics statement</title><p>The institutional review board of Helsinki University Hospital, The Ethical committee of Helsinki University Central Hospital and each study site approved the study (study number 82/99). This was a retrospective study, hence, no written or verbal consent was required.</p></sec></sec><sec id="sec009"><title>Definitions</title><p>Hospital-acquired bacteremia was defined as SAB with the first positive blood culture for <italic toggle="yes">Staphylococcus aureus</italic> obtained (1) &#8805; 48 h after hospital admission or (2) within 48 h of hospital admission with a preceding hospital discharge in the past 7 days. We applied McCabe&#8217;s criteria to classify the severity of each patient&#8217;s underlying diseases as <italic toggle="yes">healthy or nonfatal</italic>, or as <italic toggle="yes">ultimately or rapidly fatal</italic> [<xref rid="pone.0298612.ref023" ref-type="bibr">23</xref>]. The modified Duke criteria were applied to define endocarditis [<xref rid="pone.0298612.ref024" ref-type="bibr">24</xref>]. Sepsis in connection with hypotension, hypoperfusion or organ failure was classified as severe sepsis, and sepsis with arterial hypotension despite adequate fluid resuscitation was defined as septic shock [<xref rid="pone.0298612.ref025" ref-type="bibr">25</xref>]. IDS consultation within 7 days of the first positive blood culture for <italic toggle="yes">Staphylococcus aureus</italic> was documented and categorized into formal bedside consultation, informal telephone consultation or no consultation [<xref rid="pone.0298612.ref026" ref-type="bibr">26</xref>].</p></sec><sec id="sec010"><title>Diagnosis of alcoholism</title><p>Alcoholism was either determined by the treating physician or by our research team. In the latter case we looked at patients&#8217; electronic (or written) health record (EHR) and applied the WHO&#180;s clinically practical definition to determine alcoholism, namely &#8220;<italic toggle="yes">chronic continual drinking or periodic consumption of alcohol which is characterized by impaired control over drinking</italic>, <italic toggle="yes">frequent episodes of intoxication and preoccupation with alcohol and the use of alcohol despite adverse consequences</italic>&#8221; [<xref rid="pone.0298612.ref027" ref-type="bibr">27</xref>]. Due to the retrospective nature of the study, we did not use exact diagnostic entities for alcoholism defined by diagnostic criteria in the ICD-10 [<xref rid="pone.0298612.ref028" ref-type="bibr">28</xref>]. When we used a patient&#8217;s EHR (or written records) to determine alcoholism we looked at (1) records of previous visits to outpatient alcohol rehab clinics, (2) repeated visits to the emergency room due to alcohol-related issues, or (3) past medical history taken by the treating physician indicating alcoholism.</p></sec><sec id="sec011"><title>Antibiotic therapy</title><p>The standard antibiotic therapy was the semisynthetic anti-staphylococcal penicillin cloxacillin. First-line therapy in patients with a penicillin allergy or other contradictions to cloxacillin was a cephalosporin (either cefuroxime or ceftriaxone), and second-line therapy for these patients was vancomycin, clindamycin or carbapenems. In some cases, rifampicin (RMP) and/or a fluoroquinolone were provided as adjunctive therapy. The antibiotic therapy duration was regarded as correct when given intravenously for at least 28 days for a deep infection focus or when given for at least 14 days in the absence of any deep infection. Detailed information on antimicrobial indications, dosages and administration routes has been provided previously [<xref rid="pone.0298612.ref029" ref-type="bibr">29</xref>].</p></sec><sec id="sec012"><title>Outcome</title><p>The primary endpoint was mortality at 28 and 90 days. Secondary endpoints were the prevalence of deep infection foci, time to defervescence and length of hospitalization.</p></sec><sec id="sec013"><title>Statistical analyses</title><p>Categorical variables were compared with Pearson&#8217;s <italic toggle="yes">X</italic>
<sup>2</sup> test and non-categorical variables with the Student&#8217;s <italic toggle="yes">t</italic>-<italic toggle="yes">test</italic>. Odds ratios (OR) with 95% confidence intervals (CI) were calculated. Univariate factors with <italic toggle="yes">p</italic> &lt; 0.1 were entered into multivariate logistic regression model analysis for estimation of parameters associated with outcome. No missing data imputation analyses were performed. The multivariate analyses were performed with available data only. Case fatalities were estimated with Kaplan-Meier graphical presentation. Tests were 2-tailed and <italic toggle="yes">p</italic> &lt; 0.05 was considered significant. Analyses were done with <italic toggle="yes">SPSS 25</italic>.<italic toggle="yes">0</italic>.<italic toggle="yes">0 IBM SPSS Version 25</italic>.<italic toggle="yes">0</italic>. <italic toggle="yes">Armonk</italic>, <italic toggle="yes">NY</italic>: <italic toggle="yes">IBM Corp</italic>.</p></sec></sec><sec sec-type="results" id="sec014"><title>Results</title><sec id="sec015"><title>Patient demographics, underlying conditions and predisposing factors</title><p>Altogether, of the total 617 SAB patients identified 83 (13%) were defined as alcoholics and 534 (87%) as non-alcoholics (<xref rid="pone.0298612.t001" ref-type="table">Table 1</xref>). Alcoholics, compared to non-alcoholics, were slightly younger on average and more frequently male (<xref rid="pone.0298612.t001" ref-type="table">Table 1</xref>). No differences were observed between the two groups in McCabe&#180;s classification of underlying conditions, however, alcoholics had significantly less cardiovascular (16% vs. 31%) and chronic kidney disease (5% vs. 15%). Alcoholics, compared to non-alcoholics had significantly more acute or chronic liver disease (19% vs. 10%) including higher MELD scores, indicating a higher occurrence of severe or end-stage liver disease. However, no difference was seen in Maddrey&#180;s scores (<xref rid="pone.0298612.t001" ref-type="table">Table 1</xref>). There were not any significant differences in the rates of foreign bodies inserted within the past year. There was a non-significant trend towards less surgical procedures (10% vs. 21%) in the past three months in alcoholics compared to non-alcoholics (<xref rid="pone.0298612.t001" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="pone.0298612.t001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0298612.t001</object-id><label>Table 1</label><caption><title>Patient demographics, underlying conditions, and predisposing factors in patients with methicillin-sensitive <italic toggle="yes">Staphylococcus aureus</italic> bacteremia.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0298612.t001g" position="float" orientation="portrait" xlink:href="pone.0298612.t001.jpg"/><table frame="hsides" rules="groups" cellspacing="0" style="border-collapse:collapse"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" style="background-color:#D9D9D9" colspan="1">Parameters</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Total</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Alcoholics</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Non-alcoholics</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">OR</th><th align="center" rowspan="2" style="background-color:#D9D9D9" colspan="1">P-value</th></tr><tr><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">n = 617</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">n = 83 (13%)</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">n = 534 (87%)</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">(95% CI)</th></tr></thead><tbody><tr><td align="left" style="border-bottom-width:thick" rowspan="1" colspan="1">
<bold>Demographics</bold>
</td><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (years) &gt; 60, n (%)</td><td align="center" rowspan="1" colspan="1">287 (47)</td><td align="center" rowspan="1" colspan="1">29 (35)</td><td align="center" rowspan="1" colspan="1">258 (48)</td><td align="center" rowspan="1" colspan="1">0.58 (0.36&#8211;0.93)</td><td align="center" rowspan="1" colspan="1">0.023</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years), mean &#177; SD</td><td align="center" rowspan="1" colspan="1">617 (100)</td><td align="center" rowspan="1" colspan="1">55.8 &#177; 12</td><td align="center" rowspan="1" colspan="1">57.0 &#177; 18</td><td align="center" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="center" rowspan="1" colspan="1">0.464</td></tr><tr><td align="left" rowspan="1" colspan="1">Male, n (%)</td><td align="center" rowspan="1" colspan="1">384 (62)</td><td align="center" rowspan="1" colspan="1">64 (77)</td><td align="center" rowspan="1" colspan="1">320 (60)</td><td align="center" rowspan="1" colspan="1">2.25 (1.31&#8211;3.87)</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" style="border-bottom-width:thick" rowspan="1" colspan="1">
<bold>Underlying conditions</bold>
</td><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Healthy or non-fatal, <xref rid="t001fn002" ref-type="table-fn"><bold><sup>A</sup></bold></xref> n (%)</td><td align="center" rowspan="1" colspan="1">436 (71)</td><td align="center" rowspan="1" colspan="1">56 (67)</td><td align="center" rowspan="1" colspan="1">380 (71)</td><td align="center" rowspan="1" colspan="1">0.84 (0.51&#8211;1.38)</td><td align="center" rowspan="1" colspan="1">0.492</td></tr><tr><td align="left" rowspan="1" colspan="1">Ultimately or rapidly fatal, <xref rid="t001fn002" ref-type="table-fn"><bold><sup>A</sup></bold></xref> n (%)</td><td align="center" rowspan="1" colspan="1">181 (29)</td><td align="center" rowspan="1" colspan="1">27 (33)</td><td align="center" rowspan="1" colspan="1">154 (29)</td><td align="center" rowspan="1" colspan="1">1.19 (0.73&#8211;1.95)</td><td align="center" rowspan="1" colspan="1">0.492</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular disease, n (%)</td><td align="center" rowspan="1" colspan="1">181 (29)</td><td align="center" rowspan="1" colspan="1">13 (16)</td><td align="center" rowspan="1" colspan="1">168 (31)</td><td align="center" rowspan="1" colspan="1">0.47 (0.24&#8211;0.92)</td><td align="center" rowspan="1" colspan="1">0.025</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart valve disease, n (%)</td><td align="center" rowspan="1" colspan="1">66 (11)</td><td align="center" rowspan="1" colspan="1">2 (2)</td><td align="center" rowspan="1" colspan="1">64 (12)</td><td align="center" rowspan="1" colspan="1">0.22 (0.05&#8211;0.91)</td><td align="center" rowspan="1" colspan="1">0.023</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary disease, n (%)</td><td align="center" rowspan="1" colspan="1">77 (13)</td><td align="center" rowspan="1" colspan="1">8 (10)</td><td align="center" rowspan="1" colspan="1">69 (13)</td><td align="center" rowspan="1" colspan="1">0.92 (0.42&#8211;2.02)</td><td align="center" rowspan="1" colspan="1">0.812</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td align="center" rowspan="1" colspan="1">108 (18)</td><td align="center" rowspan="1" colspan="1">16 (19)</td><td align="center" rowspan="1" colspan="1">92 (17)</td><td align="center" rowspan="1" colspan="1">1.58 (0.83&#8211;3.00)</td><td align="center" rowspan="1" colspan="1">0.164</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetic complications, n (%)</td><td align="center" rowspan="1" colspan="1">70 (11)</td><td align="center" rowspan="1" colspan="1">7 (8)</td><td align="center" rowspan="1" colspan="1">63 (12)</td><td align="center" rowspan="1" colspan="1">0.86 (0.37&#8211;2.01)</td><td align="center" rowspan="1" colspan="1">0.736</td></tr><tr><td align="left" rowspan="1" colspan="1">Acute or chronic liver disease, n (%)</td><td align="center" rowspan="1" colspan="1">67 (11)</td><td align="center" rowspan="1" colspan="1">16 (19)</td><td align="center" rowspan="1" colspan="1">51 (10)</td><td align="center" rowspan="1" colspan="1">3.25 (1.66&#8211;6.33)</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">MELD score <xref rid="t001fn003" ref-type="table-fn"><sup>B</sup></xref> (points), mean&#160;&#177; SD</td><td align="center" rowspan="1" colspan="1">67 (11)</td><td align="center" rowspan="1" colspan="1">16.0 &#177; 7.1</td><td align="center" rowspan="1" colspan="1">10.3 &#177; 4.5</td><td align="center" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="center" rowspan="1" colspan="1">0.015</td></tr><tr><td align="left" rowspan="1" colspan="1">Maddrey&#180;s score <xref rid="t001fn004" ref-type="table-fn"><sup>C</sup></xref> (points), mean&#160;&#177; SD</td><td align="center" rowspan="1" colspan="1">67 (11)</td><td align="center" rowspan="1" colspan="1">100 &#177; 94</td><td align="center" rowspan="1" colspan="1">87 &#177; 101</td><td align="center" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="center" rowspan="1" colspan="1">0.450</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic kidney disease, n (%)</td><td align="center" rowspan="1" colspan="1">83 (14)</td><td align="center" rowspan="1" colspan="1">4 (5)</td><td align="center" rowspan="1" colspan="1">79 (15)</td><td align="center" rowspan="1" colspan="1">0.29 (0.10&#8211;0.82)</td><td align="center" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" rowspan="1" colspan="1">Dialysis care, n (%)</td><td align="center" rowspan="1" colspan="1">65 (11)</td><td align="center" rowspan="1" colspan="1">3 (4)</td><td align="center" rowspan="1" colspan="1">63 (12)</td><td align="center" rowspan="1" colspan="1">0.29 (0.09&#8211;0.93)</td><td align="center" rowspan="1" colspan="1">0.027</td></tr><tr><td align="left" rowspan="1" colspan="1">Any malignancy, n (%)</td><td align="center" rowspan="1" colspan="1">63 (10)</td><td align="center" rowspan="1" colspan="1">6 (7)</td><td align="center" rowspan="1" colspan="1">57 (11)</td><td align="center" rowspan="1" colspan="1">0.82 (0.33&#8211;2.00)</td><td align="center" rowspan="1" colspan="1">0.655</td></tr><tr><td align="left" rowspan="1" colspan="1">Hematological malignancy, n (%)</td><td align="center" rowspan="1" colspan="1">39 (6)</td><td align="center" rowspan="1" colspan="1">2 (2)</td><td align="center" rowspan="1" colspan="1">37 (7)</td><td align="center" rowspan="1" colspan="1">0.33 (0.08&#8211;1.40)</td><td align="center" rowspan="1" colspan="1">0.115</td></tr><tr><td align="left" rowspan="1" colspan="1">Immunosuppressive treatment, n (%)</td><td align="center" rowspan="1" colspan="1">58 (9)</td><td align="center" rowspan="1" colspan="1">3 (4)</td><td align="center" rowspan="1" colspan="1">55 (10)</td><td align="center" rowspan="1" colspan="1">0.40 (0.12&#8211;1.32)</td><td align="center" rowspan="1" colspan="1">0.119</td></tr><tr><td align="left" rowspan="1" colspan="1">HIV infection, n (%)</td><td align="center" rowspan="1" colspan="1">8 (1)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">8 (1)</td><td align="center" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="center" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" style="border-bottom-width:thick" rowspan="1" colspan="1">
<bold>Predisposing factors, n (%)</bold>
</td><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Injection drug use <xref rid="t001fn005" ref-type="table-fn"><bold><sup>D</sup></bold></xref></td><td align="center" rowspan="1" colspan="1">44 (7)</td><td align="center" rowspan="1" colspan="1">2 (2)</td><td align="center" rowspan="1" colspan="1">42 (8)</td><td align="center" rowspan="1" colspan="1">0.35 (0.08&#8211;1.50)</td><td align="center" rowspan="1" colspan="1">0.141</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior skin disease or wound <xref rid="t001fn005" ref-type="table-fn"><bold><sup>D</sup></bold></xref></td><td align="center" rowspan="1" colspan="1">234 (38)</td><td align="center" rowspan="1" colspan="1">29 (41)</td><td align="center" rowspan="1" colspan="1">194 (37)</td><td align="center" rowspan="1" colspan="1">1.48 (0.80&#8211;2.73)</td><td align="center" rowspan="1" colspan="1">0.208</td></tr><tr><td align="left" rowspan="1" colspan="1">Surgical procedure <xref rid="t001fn006" ref-type="table-fn"><bold><sup>E</sup></bold></xref></td><td align="center" rowspan="1" colspan="1">119 (19)</td><td align="center" rowspan="1" colspan="1">8 (10)</td><td align="center" rowspan="1" colspan="1">111 (21)</td><td align="center" rowspan="1" colspan="1">0.49 (0.22&#8211;1.08)</td><td align="center" rowspan="1" colspan="1">0.071</td></tr><tr><td align="left" rowspan="1" colspan="1">Foreign body <xref rid="t001fn007" ref-type="table-fn"><bold><sup>F</sup></bold></xref></td><td align="center" rowspan="1" colspan="1">112 (18)</td><td align="center" rowspan="1" colspan="1">13 (16)</td><td align="center" rowspan="1" colspan="1">99 (19)</td><td align="center" rowspan="1" colspan="1">1.06 (0.54&#8211;2.09)</td><td align="center" rowspan="1" colspan="1">0.862</td></tr><tr><td align="left" rowspan="1" colspan="1">Central venous catheter</td><td align="center" rowspan="1" colspan="1">58 (9)</td><td align="center" rowspan="1" colspan="1">7 (8)</td><td align="center" rowspan="1" colspan="1">51 (10)</td><td align="center" rowspan="1" colspan="1">1.11 (0.47&#8211;2.60)</td><td align="center" rowspan="1" colspan="1">0.814</td></tr><tr><td align="left" rowspan="1" colspan="1">Any vascular foreign body</td><td align="center" rowspan="1" colspan="1">82 (13)</td><td align="center" rowspan="1" colspan="1">8 (10)</td><td align="center" rowspan="1" colspan="1">74 (14)</td><td align="center" rowspan="1" colspan="1">0.83 (0.37&#8211;1.85)</td><td align="center" rowspan="1" colspan="1">0.653</td></tr><tr><td align="left" rowspan="1" colspan="1">Orthopedic foreign body</td><td align="center" rowspan="1" colspan="1">66 (11)</td><td align="center" rowspan="1" colspan="1">7 (8)</td><td align="center" rowspan="1" colspan="1">59 (11)</td><td align="center" rowspan="1" colspan="1">0.94 (0.40&#8211;2.18)</td><td align="center" rowspan="1" colspan="1">0.876</td></tr><tr><td align="left" rowspan="1" colspan="1">Prosthetic heart valve</td><td align="center" rowspan="1" colspan="1">18 (3)</td><td align="center" rowspan="1" colspan="1">1 (1)</td><td align="center" rowspan="1" colspan="1">17 (3)</td><td align="center" rowspan="1" colspan="1">0.46 (0.06&#8211;3.51)</td><td align="center" rowspan="1" colspan="1">0.440</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Data are number of patients (%), odds ratios (OR) (95% confidence intervals). HIV, human immunodeficiency virus.</p></fn><fn id="t001fn002"><p><bold><sup>A</sup></bold> Classification according to McCabe and Jackson [<xref rid="pone.0298612.ref023" ref-type="bibr">23</xref>].</p></fn><fn id="t001fn003"><p><sup>B</sup> MELD score, Model for End-stage Liver Disease [<xref rid="pone.0298612.ref030" ref-type="bibr">30</xref>].</p></fn><fn id="t001fn004"><p><sup>C</sup> Maddrey&#180;s score, assessment of probability for alcohol induced hepatitis [<xref rid="pone.0298612.ref031" ref-type="bibr">31</xref>].</p></fn><fn id="t001fn005"><p><bold><sup>D</sup></bold> During the last six months.</p></fn><fn id="t001fn006"><p><bold><sup>E</sup></bold> Within 90 days.</p></fn><fn id="t001fn007"><p><bold><sup>F</sup></bold> Inserted within the last year.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec016"><title>Severity of illness and infection foci</title><p>Illness severity was greater in alcoholics than non-alcoholics, as alcoholics had higher rates of severe sepsis (25% vs. 7%), intensive care unit (ICU) admission (39% vs. 17%), inotropic therapy (14% vs. 4%), artificial ventilation (13% vs. 4%) and overall higher Pitt bacteremia scores (<xref rid="pone.0298612.t002" ref-type="table">Table 2</xref> and <xref rid="pone.0298612.s001" ref-type="supplementary-material">S1 Fig</xref>). In contrast, hospital-acquired SAB was significantly more common in non-alcoholics than alcoholics (56% vs. 37%) (<xref rid="pone.0298612.t002" ref-type="table">Table 2</xref>). However, the total deep infection foci rates in alcoholics and non-alcoholics were similar (71% vs. 76%). Regarding subgroups of deep infection foci, alcoholics had significantly more often pneumonia (49% vs. 35%) and less endocarditis (7% vs. 16%) and less foreign body infections (7% vs 16%) than non-alcoholics (<xref rid="pone.0298612.t002" ref-type="table">Table 2</xref> and <xref rid="pone.0298612.s001" ref-type="supplementary-material">S1 Fig</xref>).</p><table-wrap position="float" id="pone.0298612.t002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0298612.t002</object-id><label>Table 2</label><caption><title>The course, severity, and clinical management of MS-SAB.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0298612.t002g" position="float" orientation="portrait" xlink:href="pone.0298612.t002.jpg"/><table frame="hsides" rules="groups" cellspacing="0" style="border-collapse:collapse"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" style="background-color:#D9D9D9" colspan="1">Parameters</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Total</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Alcoholics</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Non-alcoholics</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">OR</th><th align="center" rowspan="2" style="background-color:#D9D9D9" colspan="1">P-value</th></tr><tr><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">n = 617</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">n = 83 (13%)</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">n = 534 (87%)</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">(95% CI)</th></tr></thead><tbody><tr><td align="left" style="border-bottom-width:thick" rowspan="1" colspan="1">
<bold>Course and severity of disease</bold>
</td><td align="left" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="left" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="left" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="left" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="left" style="border-bottom-width:thick" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Pitt bacteremia score &gt; 3</td><td align="center" rowspan="1" colspan="1">65 (11)</td><td align="center" rowspan="1" colspan="1">24 (29)</td><td align="center" rowspan="1" colspan="1">41 (8)</td><td align="center" rowspan="1" colspan="1">4.93 (2.78&#8211;8.75)</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Pitt bacteremia score &gt; 5</td><td align="center" rowspan="1" colspan="1">32 (5)</td><td align="center" rowspan="1" colspan="1">14 (17)</td><td align="center" rowspan="1" colspan="1">18 (3)</td><td align="center" rowspan="1" colspan="1">5.84 (2.78&#8211;12.28)</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Pitt Score, mean &#177; SD</td><td align="center" rowspan="1" colspan="1">602 (98)</td><td align="center" rowspan="1" colspan="1">1.90 &#177; 2.62</td><td align="center" rowspan="1" colspan="1">0.63 &#177; 1.43</td><td align="center" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Emergent dialysis</td><td align="center" rowspan="1" colspan="1">22 (4)</td><td align="center" rowspan="1" colspan="1">5 (6)</td><td align="center" rowspan="1" colspan="1">17 (3)</td><td align="center" rowspan="1" colspan="1">1.95 (0.70&#8211;5.43)</td><td align="center" rowspan="1" colspan="1">0.194</td></tr><tr><td align="left" rowspan="1" colspan="1">Inotropic therapy</td><td align="center" rowspan="1" colspan="1">32 (5)</td><td align="center" rowspan="1" colspan="1">12 (14)</td><td align="center" rowspan="1" colspan="1">20 (4)</td><td align="center" rowspan="1" colspan="1">4.34 (2.04&#8211;9.27)</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Artificial ventilation</td><td align="center" rowspan="1" colspan="1">31 (5)</td><td align="center" rowspan="1" colspan="1">11 (13)</td><td align="center" rowspan="1" colspan="1">20 (4)</td><td align="center" rowspan="1" colspan="1">3.93 (1.81&#8211;8.53)</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe sepsis</td><td align="center" rowspan="1" colspan="1">56 (9)</td><td align="center" rowspan="1" colspan="1">21 (25)</td><td align="center" rowspan="1" colspan="1">35 (7)</td><td align="center" rowspan="1" colspan="1">4.83 (2.65&#8211;8.82)</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU</td><td align="center" rowspan="1" colspan="1">124 (20)</td><td align="center" rowspan="1" colspan="1">32 (39)</td><td align="center" rowspan="1" colspan="1">92 (17)</td><td align="center" rowspan="1" colspan="1">3.01 (1.84&#8211;4.95)</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Deep infection foci</td><td align="center" rowspan="1" colspan="1">464 (75)</td><td align="center" rowspan="1" colspan="1">59 (71)</td><td align="center" rowspan="1" colspan="1">405 (76)</td><td align="center" rowspan="1" colspan="1">0.78 (0.47&#8211;1.31)</td><td align="center" rowspan="1" colspan="1">0.350</td></tr><tr><td align="left" rowspan="1" colspan="1">Pneumonia</td><td align="center" rowspan="1" colspan="1">228 (37)</td><td align="center" rowspan="1" colspan="1">41 (49)</td><td align="center" rowspan="1" colspan="1">187 (35)</td><td align="center" rowspan="1" colspan="1">1.81 (1.14&#8211;2.89)</td><td align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">Endocarditis</td><td align="center" rowspan="1" colspan="1">91 (15)</td><td align="center" rowspan="1" colspan="1">6 (7)</td><td align="center" rowspan="1" colspan="1">85 (16)</td><td align="center" rowspan="1" colspan="1">0.41 (0.17&#8211;0.98)</td><td align="center" rowspan="1" colspan="1">0.038</td></tr><tr><td align="left" rowspan="1" colspan="1">Mediastinitis</td><td align="center" rowspan="1" colspan="1">27 (4)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">27 (5)</td><td align="center" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="center" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Meningitis</td><td align="center" rowspan="1" colspan="1">7 (1)</td><td align="center" rowspan="1" colspan="1">1 (1)</td><td align="center" rowspan="1" colspan="1">6 (1)</td><td align="center" rowspan="1" colspan="1">1.07 (0.13&#8211;9.03)</td><td align="center" rowspan="1" colspan="1">0.948</td></tr><tr><td align="left" rowspan="1" colspan="1">Septic arthritis</td><td align="center" rowspan="1" colspan="1">72 (12)</td><td align="center" rowspan="1" colspan="1">12 (14)</td><td align="center" rowspan="1" colspan="1">60 (11)</td><td align="center" rowspan="1" colspan="1">1.34 (0.69&#8211;2.60)</td><td align="center" rowspan="1" colspan="1">0.395</td></tr><tr><td align="left" rowspan="1" colspan="1">Osteomyelitis</td><td align="center" rowspan="1" colspan="1">171 (28)</td><td align="center" rowspan="1" colspan="1">18 (22)</td><td align="center" rowspan="1" colspan="1">153 (29)</td><td align="center" rowspan="1" colspan="1">0.69 (0.40&#8211;1.20)</td><td align="center" rowspan="1" colspan="1">0.187</td></tr><tr><td align="left" rowspan="1" colspan="1">Septic arthritis or osteomyelitis</td><td align="center" rowspan="1" colspan="1">212 (35)</td><td align="center" rowspan="1" colspan="1">27 (33)</td><td align="center" rowspan="1" colspan="1">185 (35)</td><td align="center" rowspan="1" colspan="1">0.91 (0.55&#8211;1.48)</td><td align="center" rowspan="1" colspan="1">0.698</td></tr><tr><td align="left" rowspan="1" colspan="1">Foreign body infection</td><td align="center" rowspan="1" colspan="1">91 (15)</td><td align="center" rowspan="1" colspan="1">6 (7)</td><td align="center" rowspan="1" colspan="1">85 (16)</td><td align="center" rowspan="1" colspan="1">0.41 (0.17&#8211;0.98)</td><td align="center" rowspan="1" colspan="1">0.038</td></tr><tr><td align="left" rowspan="1" colspan="1">Deep-seated abscesses</td><td align="center" rowspan="1" colspan="1">238 (39)</td><td align="center" rowspan="1" colspan="1">28 (34)</td><td align="center" rowspan="1" colspan="1">210 (39)</td><td align="center" rowspan="1" colspan="1">0.79 (0.48&#8211;1.28)</td><td align="center" rowspan="1" colspan="1">0.330</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital acquired SAB</td><td align="center" rowspan="1" colspan="1">328 (53)</td><td align="center" rowspan="1" colspan="1">31 (37)</td><td align="center" rowspan="1" colspan="1">297 (56)</td><td align="center" rowspan="1" colspan="1">0.48 (0.30&#8211;0.77)</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Days to defervescence, mean &#177; SD</td><td align="center" rowspan="1" colspan="1">580 (94)</td><td align="center" rowspan="1" colspan="1">7 &#177; 9</td><td align="center" rowspan="1" colspan="1">6 &#177; 9</td><td align="center" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="center" rowspan="1" colspan="1">0.519</td></tr><tr><td align="left" rowspan="1" colspan="1">Follow-up (days) <xref rid="t002fn002" ref-type="table-fn"><bold><sup>A</sup></bold></xref>, mean &#177; SD</td><td align="center" rowspan="1" colspan="1">616 (&#8764;100)</td><td align="center" rowspan="1" colspan="1">69 &#177; 33</td><td align="center" rowspan="1" colspan="1">80 &#177; 25</td><td align="center" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospitalization duration (days), mean &#177; SD</td><td align="center" rowspan="1" colspan="1">586 (95)</td><td align="center" rowspan="1" colspan="1">35 &#177; 27</td><td align="center" rowspan="1" colspan="1">35 &#177; 31</td><td align="center" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="center" rowspan="1" colspan="1">0.988</td></tr><tr><td align="left" rowspan="1" colspan="1">Fever duration &lt; 7 days</td><td align="center" rowspan="1" colspan="1">452 (73)</td><td align="center" rowspan="1" colspan="1">54 (65)</td><td align="center" rowspan="1" colspan="1">398 (75)</td><td align="center" rowspan="1" colspan="1">0.76 (0.43&#8211;1.34)</td><td align="center" rowspan="1" colspan="1">0.349</td></tr><tr><td align="left" rowspan="1" colspan="1">Deceased within 7 days</td><td align="center" rowspan="1" colspan="1">26 (4)</td><td align="center" rowspan="1" colspan="1">6 (7)</td><td align="center" rowspan="1" colspan="1">20 (4)</td><td align="center" rowspan="1" colspan="1">2.00 (0.78&#8211;5.14)</td><td align="center" rowspan="1" colspan="1">0.780</td></tr><tr><td align="left" rowspan="1" colspan="1">Deceased within 14 days</td><td align="center" rowspan="1" colspan="1">49 (8)</td><td align="center" rowspan="1" colspan="1">12 (14)</td><td align="center" rowspan="1" colspan="1">37 (7)</td><td align="center" rowspan="1" colspan="1">2.27 (1.13&#8211;4.56)</td><td align="center" rowspan="1" colspan="1">0.018</td></tr><tr><td align="left" rowspan="1" colspan="1">Deceased within 28 days</td><td align="center" rowspan="1" colspan="1">80 (13)</td><td align="center" rowspan="1" colspan="1">20 (24)</td><td align="center" rowspan="1" colspan="1">60 (11)</td><td align="center" rowspan="1" colspan="1">2.51 (1.41&#8211;4.44)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Decreased within 90 days</td><td align="center" rowspan="1" colspan="1">116 (19)</td><td align="center" rowspan="1" colspan="1">26 (31)</td><td align="center" rowspan="1" colspan="1">90 (17)</td><td align="center" rowspan="1" colspan="1">2.25 (1.34&#8211;3.77)</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" style="border-bottom-width:thick" rowspan="1" colspan="1">
<bold>Clinical management</bold>
</td><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom-width:thick" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Bedside consultation <xref rid="t002fn003" ref-type="table-fn"><bold><sup>B</sup></bold></xref></td><td align="center" rowspan="1" colspan="1">520 (84)</td><td align="center" rowspan="1" colspan="1">64 (77)</td><td align="center" rowspan="1" colspan="1">456 (85)</td><td align="center" rowspan="1" colspan="1">0.58 (0.33&#8211;1.01)</td><td align="center" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" rowspan="1" colspan="1">Telephone consultation <xref rid="t002fn003" ref-type="table-fn"><bold><sup>B</sup></bold></xref></td><td align="center" rowspan="1" colspan="1">62 (10)</td><td align="center" rowspan="1" colspan="1">13 (16)</td><td align="center" rowspan="1" colspan="1">49 (9)</td><td align="center" rowspan="1" colspan="1">1.84 (0.95&#8211;3.56)</td><td align="center" rowspan="1" colspan="1">0.067</td></tr><tr><td align="left" rowspan="1" colspan="1">No consultation <xref rid="t002fn003" ref-type="table-fn"><bold><sup>B</sup></bold></xref></td><td align="center" rowspan="1" colspan="1">35 (6)</td><td align="center" rowspan="1" colspan="1">6 (7)</td><td align="center" rowspan="1" colspan="1">29 (5)</td><td align="center" rowspan="1" colspan="1">1.38 (0.55&#8211;3.42)</td><td align="center" rowspan="1" colspan="1">0.492</td></tr><tr><td align="left" rowspan="1" colspan="1">TTE</td><td align="center" rowspan="1" colspan="1">204 (33)</td><td align="center" rowspan="1" colspan="1">28 (34)</td><td align="center" rowspan="1" colspan="1">176 (33)</td><td align="center" rowspan="1" colspan="1">1.04 (0.64&#8211;1.69)</td><td align="center" rowspan="1" colspan="1">0.889</td></tr><tr><td align="left" rowspan="1" colspan="1">TEE</td><td align="center" rowspan="1" colspan="1">69 (11)</td><td align="center" rowspan="1" colspan="1">5 (1)</td><td align="center" rowspan="1" colspan="1">64 (12)</td><td align="center" rowspan="1" colspan="1">0.47 (0.18&#8211;1.21)</td><td align="center" rowspan="1" colspan="1">0.109</td></tr><tr><td align="left" rowspan="1" colspan="1">Leukocyte map</td><td align="center" rowspan="1" colspan="1">176 (29)</td><td align="center" rowspan="1" colspan="1">27 (33)</td><td align="center" rowspan="1" colspan="1">149 (28)</td><td align="center" rowspan="1" colspan="1">1.25 (0.76&#8211;2.05)</td><td align="center" rowspan="1" colspan="1">0.385</td></tr><tr><td align="left" rowspan="1" colspan="1">Full-body CT</td><td align="center" rowspan="1" colspan="1">244 (40)</td><td align="center" rowspan="1" colspan="1">35 (42)</td><td align="center" rowspan="1" colspan="1">209 (39)</td><td align="center" rowspan="1" colspan="1">1.13 (0.71&#8211;1.81)</td><td align="center" rowspan="1" colspan="1">0.599</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-staphylococcal AB at day 7</td><td align="center" rowspan="1" colspan="1">488 (79)</td><td align="center" rowspan="1" colspan="1">58 (70)</td><td align="center" rowspan="1" colspan="1">430 (81)</td><td align="center" rowspan="1" colspan="1">0.56 (0.34&#8211;0.94)</td><td align="center" rowspan="1" colspan="1">0.027</td></tr><tr><td align="left" rowspan="1" colspan="1">Cephalosporin at day 7</td><td align="center" rowspan="1" colspan="1">92 (15)</td><td align="center" rowspan="1" colspan="1">16 (19)</td><td align="center" rowspan="1" colspan="1">76 (14)</td><td align="center" rowspan="1" colspan="1">1.44 (0.79&#8211;2.61)</td><td align="center" rowspan="1" colspan="1">0.230</td></tr><tr><td align="left" rowspan="1" colspan="1">Other antibiotic at day 7</td><td align="center" rowspan="1" colspan="1">37 (6)</td><td align="center" rowspan="1" colspan="1">9 (11)</td><td align="center" rowspan="1" colspan="1">28 (5)</td><td align="center" rowspan="1" colspan="1">2.20 (1.00&#8211;4.84)</td><td align="center" rowspan="1" colspan="1">0.046</td></tr><tr><td align="left" rowspan="1" colspan="1">Correct antibiotic duration (14&#8211;28 days)</td><td align="center" rowspan="1" colspan="1">356 (58)</td><td align="center" rowspan="1" colspan="1">36 (43)</td><td align="center" rowspan="1" colspan="1">320 (60)</td><td align="center" rowspan="1" colspan="1">0.51 (0.32&#8211;0.82)</td><td align="center" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">Correct antibiotic duration (14&#8211;28 days)&#8211;adjusted <xref rid="t002fn004" ref-type="table-fn"><bold><sup>C</sup></bold></xref></td><td align="center" rowspan="1" colspan="1">327 (53)</td><td align="center" rowspan="1" colspan="1">32 (56)</td><td align="center" rowspan="1" colspan="1">295 (66)</td><td align="center" rowspan="1" colspan="1">0.65 (0.37&#8211;1.13)</td><td align="center" rowspan="1" colspan="1">0.124</td></tr><tr><td align="left" rowspan="1" colspan="1">Aminoglycoside treatment</td><td align="center" rowspan="1" colspan="1">102 (17)</td><td align="center" rowspan="1" colspan="1">9 (11)</td><td align="center" rowspan="1" colspan="1">93 (17)</td><td align="center" rowspan="1" colspan="1">0.58 (0.28&#8211;1.19)</td><td align="center" rowspan="1" colspan="1">0.134</td></tr><tr><td align="left" rowspan="1" colspan="1">Fluoroquinolone treatment</td><td align="center" rowspan="1" colspan="1">303 (49)</td><td align="center" rowspan="1" colspan="1">46 (55)</td><td align="center" rowspan="1" colspan="1">257 (48)</td><td align="center" rowspan="1" colspan="1">1.34 (0.84&#8211;2.13)</td><td align="center" rowspan="1" colspan="1">0.216</td></tr><tr><td align="left" rowspan="1" colspan="1">RMP treatment</td><td align="center" rowspan="1" colspan="1">363 (59)</td><td align="center" rowspan="1" colspan="1">35 (42)</td><td align="center" rowspan="1" colspan="1">328 (61)</td><td align="center" rowspan="1" colspan="1">0.46 (0.29&#8211;0.73)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">RMP treatment at least 14 days, n</td><td align="center" rowspan="1" colspan="1">290 (47)</td><td align="center" rowspan="1" colspan="1">27 (33)</td><td align="center" rowspan="1" colspan="1">263 (49)</td><td align="center" rowspan="1" colspan="1">0.50 (0.30&#8211;0.81)</td><td align="center" rowspan="1" colspan="1">0.005</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Data are number of patients (%), odds ratios (OR) (95% confidence intervals). ICU, intensive care unit; TTE, transthoracic echocardiography; TEE, transesophageal echocardiography; CT, computed tomography; SAB, <italic toggle="yes">Staphylococcus aureus</italic> bacteremia; AB, antibiotic; RMP, rifampicin.</p></fn><fn id="t002fn002"><p><bold><sup>A</sup></bold> Follow-up duration in days until death or discharge.</p></fn><fn id="t002fn003"><p><bold><sup>B</sup></bold> Infectious disease specialist (IDS) consultation within seven days.</p></fn><fn id="t002fn004"><p><bold><sup>C</sup></bold> We left out cases deceased within 28 days in order to control for cases of discontinued antibiotics due to death.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec017"><title>Clinical management</title><p>Altogether, 84% (n = 520) of patients had a formal bedside IDS consultation and 10% (n = 62) had an informal telephone IDS consultation, whereas 6% (n = 35) were managed without IDS consultation (<xref rid="pone.0298612.t002" ref-type="table">Table 2</xref>). No significant differences in distribution of consultation were seen when comparing alcoholics with non-alcoholics. Radiological imaging, including transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), full-body computed tomography (CT) and leukocyte indium-111 scintigraphy (leukocyte map) were provided equally to alcoholics and non-alcoholics (<xref rid="pone.0298612.t002" ref-type="table">Table 2</xref> and <xref rid="pone.0298612.s002" ref-type="supplementary-material">S2 Fig</xref>).</p><p>All patients were treated with an antibiotic effective against the cultured strain of <italic toggle="yes">Staphylococcus aureus</italic> as soon as the strain&#8217;s susceptibility data was available. The vast majority received an anti-staphylococcal penicillin (80%). Alcoholics, compared to non-alcoholics, were treated less often with an anti-staphylococcal penicillin (70% vs. 81%) and more often with a broader spectrum (other) antibiotic (11% vs. 5%) (<xref rid="pone.0298612.t002" ref-type="table">Table 2</xref> and <xref rid="pone.0298612.s002" ref-type="supplementary-material">S2 Fig</xref>). No differences were observed in adjunctive fluoroquinolone or aminoglycoside use, whereas alcoholics received less rifampicin (RMP) therapy than non-alcoholics (42% vs 61%). Proper duration of antibiotic therapy was observed less often in alcoholics compared to non-alcoholics (<xref rid="pone.0298612.t002" ref-type="table">Table 2</xref>). However, the high case-fatality among alcoholics may have resulted into shorter antibiotic courses on average. Hence, as a secondary analysis, we excluded patients who deceased within 28 days. In this secondary analysis we found no significant difference in proper duration of therapy (<xref rid="pone.0298612.t002" ref-type="table">Table 2</xref>).</p><sec id="sec018"><title>Laboratory values</title><p>No differences between alcoholics and non-alcoholics were observed in inflammatory markers, including leucocyte count and C-reactive protein, taken at initial blood culture collection and on day 3, 7 and 10 (<xref rid="pone.0298612.t003" ref-type="table">Table 3</xref>). D-dimer levels measured on day 1 were similar in alcoholics and non-alcoholics (<xref rid="pone.0298612.t003" ref-type="table">Table 3</xref>). Alcoholics had higher alanine transaminase (ALAT) levels at initial blood culture collection than non-alcoholics (<xref rid="pone.0298612.t003" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="pone.0298612.t003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0298612.t003</object-id><label>Table 3</label><caption><title>Laboratory value means in alcoholics and non-alcoholics with MS-SAB.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0298612.t003g" position="float" orientation="portrait" xlink:href="pone.0298612.t003.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">Parameters</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Alcoholics</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Non-alcoholics</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Leuk count at initial blood culture (SD), E9/l</td><td align="left" rowspan="1" colspan="1">12.6 (8.6)</td><td align="left" rowspan="1" colspan="1">12.9 (5.9)</td><td align="left" rowspan="1" colspan="1">0.718</td></tr><tr><td align="left" rowspan="1" colspan="1">Leuk count day 3 (SD), E9/l</td><td align="left" rowspan="1" colspan="1">10.8 (6.7)</td><td align="left" rowspan="1" colspan="1">10.2 (5.0)</td><td align="left" rowspan="1" colspan="1">0.450</td></tr><tr><td align="left" rowspan="1" colspan="1">Leuk count day 7 (SD), E9/l</td><td align="left" rowspan="1" colspan="1">10.0 (4.6)</td><td align="left" rowspan="1" colspan="1">9.6 (4.2)</td><td align="left" rowspan="1" colspan="1">0.510</td></tr><tr><td align="left" rowspan="1" colspan="1">Leuk count day 10 (SD), E9/l</td><td align="left" rowspan="1" colspan="1">9.4 (4.3)</td><td align="left" rowspan="1" colspan="1">9.2 (4.1)</td><td align="left" rowspan="1" colspan="1">0.788</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP at blood culture (SD), mg/l</td><td align="left" rowspan="1" colspan="1">180 (114)</td><td align="left" rowspan="1" colspan="1">174 (109)</td><td align="left" rowspan="1" colspan="1">0.733</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP day 3 (SD), mg/l</td><td align="left" rowspan="1" colspan="1">123 (93)</td><td align="left" rowspan="1" colspan="1">135 (80)</td><td align="left" rowspan="1" colspan="1">0.330</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP day 7 (SD), mg/l</td><td align="left" rowspan="1" colspan="1">81 (61)</td><td align="left" rowspan="1" colspan="1">71 (58)</td><td align="left" rowspan="1" colspan="1">0.328</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP day 10 (SD), mg/l</td><td align="left" rowspan="1" colspan="1">79 (57)</td><td align="left" rowspan="1" colspan="1">59 (54)</td><td align="left" rowspan="1" colspan="1">0.183</td></tr><tr><td align="left" rowspan="1" colspan="1">D-dimer day 1 (SD), mg/l</td><td align="left" rowspan="1" colspan="1">4.7</td><td align="left" rowspan="1" colspan="1">2.1 (1.5)</td><td align="left" rowspan="1" colspan="1">0.096</td></tr><tr><td align="left" rowspan="1" colspan="1">D-dimer day 7 (SD), mg/l</td><td align="left" rowspan="1" colspan="1">5.3</td><td align="left" rowspan="1" colspan="1">2.0 (1.7)</td><td align="left" rowspan="1" colspan="1">0.059</td></tr><tr><td align="left" rowspan="1" colspan="1">ALAT at blood culture (SD), U/l</td><td align="left" rowspan="1" colspan="1">322 (1421)</td><td align="left" rowspan="1" colspan="1">49 (79)</td><td align="left" rowspan="1" colspan="1">0.015</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>CRP, C-reactive protein; SD, standard deviation; Leuk, leukocyte; ALAT, alanine aminotransferase.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="sec019"><title>Outcome, defervescence and hospitalization</title><p>The overall case fatality at 14, 28 and 90 days was 8%, 13% and 19%, respectively. Alcoholics, compared to non-alcoholics, had significantly higher case fatality at 14 days (14% vs. 7%), 28 days (24% vs. 11%) and 90 days (31% vs. 17%) (<xref rid="pone.0298612.t002" ref-type="table">Table 2</xref> and <xref rid="pone.0298612.s003" ref-type="supplementary-material">S3 Fig</xref>). However, no differences in hospital duration or defervescence were observed between the groups (<xref rid="pone.0298612.t002" ref-type="table">Table 2</xref>).</p><p>Factors associated with 90-day mortality were evaluated separately for alcoholics and non-alcoholics (Tables <xref rid="pone.0298612.t004" ref-type="table">4</xref> and <xref rid="pone.0298612.t005" ref-type="table">5</xref>). In univariate analysis among alcoholics McCabe&#180;s ultimately or rapidly fatal classification (OR 8.88, P &lt; 0.001), Pitt bacteremia scores &gt; 5 (OR 3.63, P = 0.027), endocarditis (OR 13.33, P = 0.004) and lack of IDS consultation (OR 13.10, P = 0.005) were associated with poor prognosis (<xref rid="pone.0298612.t004" ref-type="table">Table 4</xref>). Multivariate analysis associated ultimately or rapidly fatal underlying diseases (OR 12.34, P &lt; 0.001) with poor prognosis, whereas male sex (OR 0.19, P = 0.021) and bedside IDS consultation (OR 0.19, P = 0.029) were associated with better prognosis (<xref rid="pone.0298612.t004" ref-type="table">Table 4</xref>).</p><table-wrap position="float" id="pone.0298612.t004" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0298612.t004</object-id><label>Table 4</label><caption><title>Prognostic factors in alcoholics with MS-SAB according to 90-day mortality.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0298612.t004g" position="float" orientation="portrait" xlink:href="pone.0298612.t004.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">Parameters</th><th align="left" colspan="2" style="background-color:#D9D9D9" rowspan="1">Univariate analysis</th><th align="left" colspan="2" style="background-color:#D9D9D9" rowspan="1">Multivariate analysis</th></tr><tr><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">OR (95% CI)</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">P-value</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">OR (95% CI)</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years) &gt; 60</td><td align="left" rowspan="1" colspan="1">2.56 (0.98&#8211;6.70)</td><td align="left" rowspan="1" colspan="1">0.052</td><td align="left" rowspan="1" colspan="1">3.62 (0.99&#8211;13.15)</td><td align="left" rowspan="1" colspan="1">0.051</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, male</td><td align="left" rowspan="1" colspan="1">0.40 (0.14&#8211;1.16)</td><td align="left" rowspan="1" colspan="1">0.086</td><td align="left" rowspan="1" colspan="1">0.19 (0.05&#8211;0.78)</td><td align="left" rowspan="1" colspan="1">0.021</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital acquired</td><td align="left" rowspan="1" colspan="1">0.66 (0.25&#8211;1.76)</td><td align="left" rowspan="1" colspan="1">0.403</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Pitt Bacteremia Score &gt; 3</td><td align="left" rowspan="1" colspan="1">2.37 (0.88&#8211;6.42)</td><td align="left" rowspan="1" colspan="1">0.086</td><td align="left" rowspan="1" colspan="1">1.63 (0.45&#8211;5.91)</td><td align="left" rowspan="1" colspan="1">0.460</td></tr><tr><td align="left" rowspan="1" colspan="1">Pitt Bacteremia Score &gt; 5</td><td align="left" rowspan="1" colspan="1">3.63 (1.11&#8211;11.91)</td><td align="left" rowspan="1" colspan="1">0.027</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe sepsis</td><td align="left" rowspan="1" colspan="1">1.50 (0.53&#8211;4.25)</td><td align="left" rowspan="1" colspan="1">0.439</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU</td><td align="left" rowspan="1" colspan="1">1.59 (0.62&#8211;4.07)</td><td align="left" rowspan="1" colspan="1">0.337</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Emergent dialysis</td><td align="left" rowspan="1" colspan="1">3.59 (0.56&#8211;22.91)</td><td align="left" rowspan="1" colspan="1">0.154</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Inotropic therapy</td><td align="left" rowspan="1" colspan="1">1.70 (0.48&#8211;5.97)</td><td align="left" rowspan="1" colspan="1">0.404</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Artificial ventilation</td><td align="left" rowspan="1" colspan="1">3.12 (0.86&#8211;11.38)</td><td align="left" rowspan="1" colspan="1">0.075</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Bedside consultation</td><td align="left" rowspan="1" colspan="1">0.30 (0.10&#8211;0.87)</td><td align="left" rowspan="1" colspan="1">0.023</td><td align="left" rowspan="1" colspan="1">0.19 (0.05&#8211;0.84)</td><td align="left" rowspan="1" colspan="1">0.029</td></tr><tr><td align="left" rowspan="1" colspan="1">Telephone consultation</td><td align="left" rowspan="1" colspan="1">1.46 (0.43&#8211;4.98)</td><td align="left" rowspan="1" colspan="1">0.546</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">No consultation</td><td align="left" rowspan="1" colspan="1">13.10 (1.44&#8211;118.79)</td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">All deep infection foci</td><td align="left" rowspan="1" colspan="1">2.10 (0.69&#8211;6.44)</td><td align="left" rowspan="1" colspan="1">0.189</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Pneumonia</td><td align="left" rowspan="1" colspan="1">1.30 (0.51&#8211;3.29)</td><td align="left" rowspan="1" colspan="1">0.584</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Endocarditis</td><td align="left" rowspan="1" colspan="1">13.33 (1.47&#8211;120.92)</td><td align="left" rowspan="1" colspan="1">0.004</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Rifampicin treatment</td><td align="left" rowspan="1" colspan="1">0.80 (0.31&#8211;2.06)</td><td align="left" rowspan="1" colspan="1">0.644</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Healthy or non-fatal <xref rid="t004fn002" ref-type="table-fn"><bold><sup>A</sup></bold></xref></td><td align="left" rowspan="1" colspan="1">0.11 (0.04&#8211;0.32)</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ultimately or rapidly fatal <xref rid="t004fn002" ref-type="table-fn"><bold><sup>A</sup></bold></xref></td><td align="left" rowspan="1" colspan="1">8.88 (3.08&#8211;25.57)</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td><td align="left" rowspan="1" colspan="1">12.34 (3.28&#8211;46.42)</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>ICU, intensive care unit.</p></fn><fn id="t004fn002"><p><bold><sup>A</sup></bold> Classification according to McCabe and Jackson [<xref rid="pone.0298612.ref023" ref-type="bibr">23</xref>].</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pone.0298612.t005" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0298612.t005</object-id><label>Table 5</label><caption><title>Prognostic factors in non-alcoholics with MS-SAB according to 90-day mortality.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0298612.t005g" position="float" orientation="portrait" xlink:href="pone.0298612.t005.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">Parameters</th><th align="left" colspan="2" style="background-color:#D9D9D9" rowspan="1">Univariate analysis</th><th align="left" colspan="2" style="background-color:#D9D9D9" rowspan="1">Multivariate analysis</th></tr><tr><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">OR (95% CI)</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">P-value</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">OR (95% CI)</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years) &gt; 60</td><td align="left" rowspan="1" colspan="1">3.61 (2.18&#8211;5.97)</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td><td align="left" rowspan="1" colspan="1">3.26 (1.81&#8211;5.91)</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, male</td><td align="left" rowspan="1" colspan="1">0.90 (0.57&#8211;1.42)</td><td align="left" rowspan="1" colspan="1">0.648</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital acquired</td><td align="left" rowspan="1" colspan="1">1.97 (1.21&#8211;3.19)</td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">1.39 (0.75&#8211;2.59)</td><td align="left" rowspan="1" colspan="1">0.298</td></tr><tr><td align="left" rowspan="1" colspan="1">Pitt Bacteremia Score &gt; 3</td><td align="left" rowspan="1" colspan="1">4.15 (2.12&#8211;8.12)</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td><td align="left" rowspan="1" colspan="1">2.45 (0.78&#8211;7.65)</td><td align="left" rowspan="1" colspan="1">0.124</td></tr><tr><td align="left" rowspan="1" colspan="1">Pitt Bacteremia Score &gt; 5</td><td align="left" rowspan="1" colspan="1">5.45 (2.10&#8211;14.16)</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe sepsis</td><td align="left" rowspan="1" colspan="1">4.84 (2.38&#8211;9.83)</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td><td align="left" rowspan="1" colspan="1">3.00 (1.01&#8211;8.92)</td><td align="left" rowspan="1" colspan="1">0.048</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU</td><td align="left" rowspan="1" colspan="1">2.33 (1.38&#8211;3.94)</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">1.11 (0.50&#8211;2.47)</td><td align="left" rowspan="1" colspan="1">0.801</td></tr><tr><td align="left" rowspan="1" colspan="1">Emergent dialysis</td><td align="left" rowspan="1" colspan="1">2.81 (1.01&#8211;7.81)</td><td align="left" rowspan="1" colspan="1">0.039</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Inotropic therapy</td><td align="left" rowspan="1" colspan="1">2.19 (0.82&#8211;5.87)</td><td align="left" rowspan="1" colspan="1">0.109</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Artificial ventilation</td><td align="left" rowspan="1" colspan="1">3.51 (1.39&#8211;8.86)</td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Bedside</td><td align="left" rowspan="1" colspan="1">0.38 (0.22&#8211;0.66)</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td><td align="left" rowspan="1" colspan="1">0.22 (0.08&#8211;0.61)</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">Telephone</td><td align="left" rowspan="1" colspan="1">1.91 (0.97&#8211;3.77)</td><td align="left" rowspan="1" colspan="1">0.058</td><td align="left" rowspan="1" colspan="1">0.69 (0.21&#8211;2.30)</td><td align="left" rowspan="1" colspan="1">0.544</td></tr><tr><td align="left" rowspan="1" colspan="1">No consultation</td><td align="left" rowspan="1" colspan="1">3.30 (1.50&#8211;7.24)</td><td align="left" rowspan="1" colspan="1">0.002</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">All deep infection foci</td><td align="left" rowspan="1" colspan="1">1.33 (0.76&#8211;2.33)</td><td align="left" rowspan="1" colspan="1">0.312</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Pneumonia</td><td align="left" rowspan="1" colspan="1">3.31 (2.08&#8211;5.28)</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td><td align="left" rowspan="1" colspan="1">3.56 (2.02&#8211;6.26)</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Endocarditis</td><td align="left" rowspan="1" colspan="1">1.81 (1.04&#8211;3.15)</td><td align="left" rowspan="1" colspan="1">0.035</td><td align="left" rowspan="1" colspan="1">1.99 (0.95&#8211;4.13)</td><td align="left" rowspan="1" colspan="1">0.067</td></tr><tr><td align="left" rowspan="1" colspan="1">Rifampicin treatment</td><td align="left" rowspan="1" colspan="1">0.75 (0.47&#8211;1.18)</td><td align="left" rowspan="1" colspan="1">0.210</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Healthy or non-fatal <xref rid="t005fn002" ref-type="table-fn"><bold><sup>A</sup></bold></xref></td><td align="left" rowspan="1" colspan="1">0.16 (0.10&#8211;0.26)</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;&#8208;&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ultimately or rapidly fatal <xref rid="t005fn002" ref-type="table-fn"><bold><sup>A</sup></bold></xref></td><td align="left" rowspan="1" colspan="1">6.18 (3.81&#8211;10.03)</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td><td align="left" rowspan="1" colspan="1">5.169 (2.842&#8211;9.403)</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t005fn001"><p>ICU, intensive care unit.</p></fn><fn id="t005fn002"><p><bold><sup>A</sup></bold> Classification according to McCabe and Jackson [<xref rid="pone.0298612.ref023" ref-type="bibr">23</xref>].</p></fn></table-wrap-foot></table-wrap><p>For non-alcoholics univariate analysis associated age over 60 years (OR 3.61, P &lt; 0.001), McCabe&#180;s ultimately or rapidly fatal classification (OR 6.18, P &lt; 0.001), hospital acquired SAB (OR 1.97, P = 0.005), Pitt bacteremia score &gt; 3 and &gt; 5 (OR 4.15 and OR 5.45, P &lt; 0.001, respectively), ICU treatment (OR 2.33, P = 0.001), pneumonia (OR 3.31, P &lt; 0.001), endocarditis (OR 1.81, P = 0.035) and lack of IDS consultation (OR 3.30, P = 0.002) with poor prognosis (<xref rid="pone.0298612.t005" ref-type="table">Table 5</xref>). Bedside IDS consultation (OR 0.38, P &lt; 0.001) was associated with better prognosis (<xref rid="pone.0298612.t005" ref-type="table">Table 5</xref>). Multivariate analysis associated age &gt; 60 (OR 3.27, P &lt; 0.001), McCabe&#180;s ultimately or rapidly fatal classification (OR 5.17, P &lt; 0.001), severe sepsis (OR 3.00, P = 0.048) and pneumonia (OR 3.56, P &lt; 0.001) with poor prognosis, and bedside IDS consultation (OR 0.22, P = 0.004) with better prognosis (<xref rid="pone.0298612.t005" ref-type="table">Table 5</xref>).</p><p>When looking at only SAB patients with acute or chronic liver disease (n = 67), alcoholics compared to non-alcoholics had significantly higher case fatality at 28 days (31% vs 4%) and 90 days (50% vs. 6%). However, when excluding SAB patients with acute or chronic liver diseases, a trend (statistically non-significant) towards higher case fatality was observed in alcoholics (n = 32), compared to non-alcoholics (n = 331), at 28 days (19% vs. 6%) and 90 days (19% vs. 18%).</p></sec></sec><sec sec-type="conclusions" id="sec020"><title>Discussion</title><p>The main finding of the present study was a higher illness severity at initial blood culture collection in alcoholics versus non-alcoholics. Alcoholics had a case fatality rate during the 90-day follow-up period double that of non-alcoholics. Alcoholics had equally many deep infection foci, but the type of infection foci differed from those of non-alcoholics. Half of alcoholics had pneumonia, but endocarditis was less common among them. Differences with respect to age, demographics, underlying conditions and clinical management between alcoholics and non-alcoholics were marginal. When accounting for all prognostic parameters, alcoholics and non-alcoholics that were treated without bedside infectious disease specialist (IDS) consultation had 5-fold higher odds of a fatal outcome.</p><p>The connection between alcoholism and increased risk and severity of infectious diseases, including blood culture positive infections, is well documented [<xref rid="pone.0298612.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0298612.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0298612.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0298612.ref032" ref-type="bibr">32</xref>, <xref rid="pone.0298612.ref033" ref-type="bibr">33</xref>]. Prior reports have documented that alcoholics make up 7&#8211;14% of SAB patients [<xref rid="pone.0298612.ref011" ref-type="bibr">11</xref>&#8211;<xref rid="pone.0298612.ref014" ref-type="bibr">14</xref>]. In our material the proportion of SAB patients classified as alcoholics (13%) was in the upper range. We observed a non-significant trend towards more ultimately or rapidly fatal disease classification according to McCabe&#180;s classification in alcoholics, however, when we excluded chronic liver disease this trend shifted to the opposite. Hence, the slightly higher occurrence of McCabe&#180;s ultimately or rapidly fatal disease classification in alcoholics was explained solely by chronic liver disease. This may indicate that alcoholics participate in less outpatient care and thus have more undiagnosed conditions. These observations are in line with reports suggesting that alcoholics, compared to the general population, seek healthcare services less frequently due to psychiatric illness, poorer access and mistrust in healthcare services and lack of a social support network [<xref rid="pone.0298612.ref034" ref-type="bibr">34</xref>, <xref rid="pone.0298612.ref035" ref-type="bibr">35</xref>].</p><p>Previous SAB studies report occurrence of severe sepsis in 14%&#8211; 25% and ICU treatment in 10%&#8211; 36% of patients [<xref rid="pone.0298612.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0298612.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0298612.ref014" ref-type="bibr">14</xref>, <xref rid="pone.0298612.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0298612.ref036" ref-type="bibr">36</xref>]. These observations are in line with the results of non-alcoholics in the present study. However, the severity of illness in alcoholics was far greater. One fourth of alcoholics presented with severe sepsis and almost two fifths of alcoholics required ICU treatment. More severe disease already upon presentation is most probably due to delayed health care seeking among alcoholics [<xref rid="pone.0298612.ref034" ref-type="bibr">34</xref>, <xref rid="pone.0298612.ref035" ref-type="bibr">35</xref>, <xref rid="pone.0298612.ref037" ref-type="bibr">37</xref>]. Other possible factors that might affect the more severe disease among alcoholics are the effects of chronic alcohol use on immune system and general health. Chronic alcohol abuse is associated with malnutrition, poor dental hygiene and increased aspiration risk, and alcohol induced subclinical immunosuppression [<xref rid="pone.0298612.ref005" ref-type="bibr">5</xref>&#8211;<xref rid="pone.0298612.ref008" ref-type="bibr">8</xref>]. Recent studies have connected alcohol abuse and alcohol-related liver diseases to reduced levels of blood cell subgroups including monocytes and natural killer cells, as well as interleukin-1 levels and diminished complement pathway functioning, increasing the risk for infectious diseases [<xref rid="pone.0298612.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0298612.ref039" ref-type="bibr">39</xref>]. In fact, alcoholics had more pneumonia although deep infection foci were equally common in alcoholics and non-alcoholics.</p><p>Considering the whole patient cohort, alcoholics received less narrow spectrum antistaphylococcal antibiotics, less adjunctive rifampicin therapy and more broad-spectrum antibiotic treatment such as clindamycin or carbapenems than non-alcoholics. Furthermore, alcoholics were provided with the correct durations of antimicrobial therapy less frequently than non-alcoholics. The greater use of broad-spectrum antimicrobial therapies in alcoholics is most likely related to the high degree of ICU treatment required in that group. Severely ill patients are more likely to be treated with broad spectrum antimicrobial therapy despite knowledge of the actual pathogen. This &#8220;confounding by indication&#8221; phenomenon has been described previously [<xref rid="pone.0298612.ref040" ref-type="bibr">40</xref>]. However, when excluding patients who deceased within 7 and/or 28 days, no differences in separate antibiotic regimens or proper duration of therapy were observed between alcoholics and non-alcoholics.</p><p>The present study observed an overall case fatality at day 28 and day 90 of 13% and 19%, respectively, which is lower than the mortality figures of 10%&#8211; 25% for 30-day mortality and 28%&#8211; 39% for 90-day mortality in many previous reports on SAB [<xref rid="pone.0298612.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0298612.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0298612.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0298612.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0298612.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0298612.ref036" ref-type="bibr">36</xref>]. However, the case fatality in alcoholics was significantly higher at 30 days (24%) and 90 days (31%) compared to non-alcoholics. These observations are in line with higher mortality from various infectious diseases reported in alcoholics compared to non-alcoholics, including pneumonia, sepsis and bacteremia [<xref rid="pone.0298612.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0298612.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0298612.ref041" ref-type="bibr">41</xref>].</p><p>There are weaknesses in the present study that must be accounted for when interpreting results.</p><p>First, a retrospective study design includes risk for bias due to potential differences in patient groups which we have tried to control for using multivariate analyses. Second, the diagnosis of alcoholism was recorded by the treating physician or determined based on data from patient records, and we did not apply exact diagnostic entities for alcoholism for which there are diagnostic criteria provided in the ICD-10 [<xref rid="pone.0298612.ref028" ref-type="bibr">28</xref>]. This procedure carries the risk for both under and overdiagnosis of potential alcoholics. Third, the patient data was collected in January&#8211;May 1999, January 2000 &#8211;August 2002 and 2006 &#8211;December 2007. The question of whether the clinical patient data in the study is valid to current hospital practice may be raised. Clinical practice and treatment of SAB develops continuously as new research results becomes available, however, the fundamentals of SAB management have remained unchanged throughout the years, including the importance of identification, eradication of deep infection foci and non-delayed optimal antibiotic therapy [<xref rid="pone.0298612.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0298612.ref042" ref-type="bibr">42</xref>, <xref rid="pone.0298612.ref043" ref-type="bibr">43</xref>]. The high degree of formal IDS consultation has granted documentation of relevant data, high-standard management and a high proportion of patients with verified deep infection foci. This feature of our data allowed for analysis relevant to current clinical practice, including comparison of the types and rate of deep infection foci between alcoholics and non-alcoholics, something not addressed in previous works [<xref rid="pone.0298612.ref011" ref-type="bibr">11</xref>&#8211;<xref rid="pone.0298612.ref013" ref-type="bibr">13</xref>].</p></sec><sec sec-type="conclusions" id="sec021"><title>Conclusions</title><p>The present study suggests that alcoholics, compared to non-alcoholics, have a higher degree of illness severity at the initial phase of MS-SAB and higher mortality from MS-SAB. Alcoholics, versus non-alcoholics, seem to have more potentially undiagnosed background conditions and delayed hospital arrival which may have contributed to a higher degree of illness severity and higher mortality. Thorough formal IDS consultation-guided clinical management improves MS-SAB prognosis in alcoholics. Alcoholics had an equally high rate of deep infection foci as non-alcoholics, but the type of foci differed between them. Half of alcoholics had pneumonia, but they had fewer cases of endocarditis than non-alcoholics. These findings can help physicians in risk stratification of alcoholic patients with SAB.</p></sec><sec id="sec022" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0298612.s001" position="float" content-type="local-data" orientation="portrait"><label>S1 Fig</label><caption><title>Disease severity in alcoholics and non-alcoholics with MS-SAB.</title><p>ICU, intensive care unit. *** = P &lt; 0.001; * = P &lt; 0.05.</p><p>(TIF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0298612.s001.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0298612.s002" position="float" content-type="local-data" orientation="portrait"><label>S2 Fig</label><caption><title>Clinical management of MS-SAB in alcoholics and non-alcoholics.</title><p>IDS, infectious disease specialist; TTE, transthoracic echocardiography; TEE, transesophageal echocardiography; CT, computed tomography; Anti-staph, anti-staphylococcal antibiotic; AB, antibiotic; RMP, rifampicin. * = P &lt; 0.05; ** = P &lt; 0.01.</p><p>(TIF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0298612.s002.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0298612.s003" position="float" content-type="local-data" orientation="portrait"><label>S3 Fig</label><caption><title>Three-month survival in alcoholics and non-alcoholics with MS-SAB.</title><p>P = 0.001.</p><p>(TIF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0298612.s003.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0298612.s004" position="float" content-type="local-data" orientation="portrait"><label>S1 File</label><caption><title>Dataset.</title><p>(XLSX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0298612.s004.xlsx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0298612.ref001"><label>1</label><mixed-citation publication-type="other">World Health Organization Global status report on alcohol and health 2018. [cited 1 Apr 2022]. Available: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications-detail-redirect/9789241565639" ext-link-type="uri">https://www.who.int/publications-detail-redirect/9789241565639</ext-link></mixed-citation></ref><ref id="pone.0298612.ref002"><label>2</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gupta</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Lindenauer</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>P-C</given-names></name>, <name name-style="western"><surname>Imrey</surname><given-names>PB</given-names></name>, <name name-style="western"><surname>Haessler</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Deshpande</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Association Between Alcohol Use Disorders and Outcomes of Patients Hospitalized With Community-Acquired Pneumonia</article-title>. <source>JAMA Network Open</source>. <year>2019</year>;<volume>2</volume>: <fpage>e195172</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.5172</pub-id><pub-id pub-id-type="pmid">31173120</pub-id><pub-id pub-id-type="pmcid">PMC6563577</pub-id></mixed-citation></ref><ref id="pone.0298612.ref003"><label>3</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Simou</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Britton</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Leonardi-Bee</surname><given-names>J</given-names></name>. <article-title>Alcohol and the risk of pneumonia: a systematic review and meta-analysis</article-title>. <source>BMJ Open</source>. <year>2018</year>;<volume>8</volume>: <fpage>e022344</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmjopen-2018-022344</pub-id><pub-id pub-id-type="pmid">30135186</pub-id><pub-id pub-id-type="pmcid">PMC6112384</pub-id></mixed-citation></ref><ref id="pone.0298612.ref004"><label>4</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Halavaara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>J&#228;&#228;skel&#228;inen</surname><given-names>IH</given-names></name>, <name name-style="western"><surname>Hagberg</surname><given-names>L</given-names></name>, <name name-style="western"><surname>J&#228;rvinen</surname><given-names>A</given-names></name>. <article-title>Factors associated with blood culture positivity in patients with complicated skin and skin structure infection-a population-based study</article-title>. <source>Eur J Clin Microbiol Infect Dis</source>. <year>2019</year>;<volume>38</volume>: <fpage>1351</fpage>&#8211;<lpage>1357</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10096-019-03560-9</pub-id><pub-id pub-id-type="pmid">31011854</pub-id><pub-id pub-id-type="pmcid">PMC6570775</pub-id></mixed-citation></ref><ref id="pone.0298612.ref005"><label>5</label><mixed-citation publication-type="journal"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Aberegg</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Marsh</surname><given-names>CB</given-names></name>, <etal>et al</etal>. <article-title>Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult intensive care unit patients</article-title>. <source>Crit Care Med</source>. <year>2007</year>;<volume>35</volume>: <fpage>345</fpage>&#8211;<lpage>350</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/01.CCM.0000254340.91644.B2</pub-id><pub-id pub-id-type="pmid">17205003</pub-id></mixed-citation></ref><ref id="pone.0298612.ref006"><label>6</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Moss</surname><given-names>M.</given-names></name><article-title>Epidemiology of sepsis: race, sex, and chronic alcohol abuse</article-title>. <source>Clin Infect Dis</source>. <year>2005</year>;<volume>41</volume><issue>Suppl 7</issue>: <fpage>S490</fpage>&#8211;<lpage>497</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1086/432003</pub-id><pub-id pub-id-type="pmid">16237652</pub-id></mixed-citation></ref><ref id="pone.0298612.ref007"><label>7</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pavia</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>La Mothe</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kavanagh</surname><given-names>M</given-names></name>. <article-title>Influence of alcohol on antimicrobial immunity</article-title>. <source>Biomed Pharmacother</source>. <year>2004</year>;<volume>58</volume>: <fpage>84</fpage>&#8211;<lpage>89</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.biopha.2003.12.005</pub-id><pub-id pub-id-type="pmid">14992788</pub-id></mixed-citation></ref><ref id="pone.0298612.ref008"><label>8</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Szabo</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Saha</surname><given-names>B</given-names></name>. <article-title>Alcohol&#8217;s Effect on Host Defense</article-title>. <source>Alcohol Res</source>. <year>2015</year>;<volume>37</volume>: <fpage>159</fpage>&#8211;<lpage>170</lpage>. <pub-id pub-id-type="pmid">26695755</pub-id><pub-id pub-id-type="pmcid">PMC4590613</pub-id></mixed-citation></ref><ref id="pone.0298612.ref009"><label>9</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Naber</surname><given-names>CK</given-names></name>. <article-title>Staphylococcus aureus Bacteremia: Epidemiology, Pathophysiology, and Management Strategies</article-title>. <source>Clinical Infectious Diseases</source>. <year>2009</year>;<volume>48</volume>: <fpage>S231</fpage>&#8211;<lpage>S237</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1086/598189</pub-id><pub-id pub-id-type="pmid">19374578</pub-id></mixed-citation></ref><ref id="pone.0298612.ref010"><label>10</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bai</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Lo</surname><given-names>CKL</given-names></name>, <name name-style="western"><surname>Komorowski</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Suresh</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Garg</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis</article-title>. <source>Clinical Microbiology and Infection</source>. <year>2022</year>;<volume>28</volume>: <fpage>1076</fpage>&#8211;<lpage>1084</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cmi.2022.03.015</pub-id><pub-id pub-id-type="pmid">35339678</pub-id></mixed-citation></ref><ref id="pone.0298612.ref011"><label>11</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kaech</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Elzi</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sendi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Frei</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Laifer</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Bassetti</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Course and outcome of Staphylococcus aureus bacteraemia: a retrospective analysis of 308 episodes in a Swiss tertiary-care centre</article-title>. <source>Clin Microbiol Infect</source>. <year>2006</year>;<volume>12</volume>: <fpage>345</fpage>&#8211;<lpage>352</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1469-0691.2005.01359.x</pub-id><pub-id pub-id-type="pmid">16524411</pub-id></mixed-citation></ref><ref id="pone.0298612.ref012"><label>12</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Laupland</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Church</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Mucenski</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sutherland</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>Davies</surname><given-names>HD</given-names></name>. <article-title>Population-Based Study of the Epidemiology of and the Risk Factors for Invasive Staphylococcus aureus Infections</article-title>. <source>The Journal of Infectious Diseases</source>. <year>2003</year>;<volume>187</volume>: <fpage>1452</fpage>&#8211;<lpage>1459</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1086/374621</pub-id><pub-id pub-id-type="pmid">12717627</pub-id></mixed-citation></ref><ref id="pone.0298612.ref013"><label>13</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Price</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Baker</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Heath</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Walker-Bone</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Cubbon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Curtis</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Clinical and Microbiological Determinants of Outcome in Staphylococcus aureus Bacteraemia</article-title>. <source>Int J Microbiol</source>. <year>2010</year>;<volume>2010</volume>: <fpage>654858</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2010/654858</pub-id><pub-id pub-id-type="pmid">20300477</pub-id><pub-id pub-id-type="pmcid">PMC2840372</pub-id></mixed-citation></ref><ref id="pone.0298612.ref014"><label>14</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jensen</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Wachmann</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Espersen</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Scheibel</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Skinh&#248;j</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Frimodt-M&#248;ller</surname><given-names>N</given-names></name>. <article-title>Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases</article-title>. <source>Arch Intern Med</source>. <year>2002</year>;<volume>162</volume>: <fpage>25</fpage>&#8211;<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/archinte.162.1.25</pub-id><pub-id pub-id-type="pmid">11784216</pub-id></mixed-citation></ref><ref id="pone.0298612.ref015"><label>15</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Forsblom</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ruotsalainen</surname><given-names>E</given-names></name>, <name name-style="western"><surname>M&#246;lk&#228;nen</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ollgren</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lyytik&#228;inen</surname><given-names>O</given-names></name>, <name name-style="western"><surname>J&#228;rvinen</surname><given-names>A</given-names></name>. <article-title>Predisposing factors, disease progression and outcome in 430 prospectively followed patients of healthcare- and community-associated Staphylococcus aureus bacteraemia</article-title>. <source>J Hosp Infect</source>. <year>2011</year>;<volume>78</volume>: <fpage>102</fpage>&#8211;<lpage>107</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jhin.2011.03.010</pub-id><pub-id pub-id-type="pmid">21511366</pub-id></mixed-citation></ref><ref id="pone.0298612.ref016"><label>16</label><mixed-citation publication-type="journal"><name name-style="western"><surname>van Hal</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>SO</given-names></name>, <name name-style="western"><surname>Vaska</surname><given-names>VL</given-names></name>, <name name-style="western"><surname>Espedido</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Paterson</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Gosbell</surname><given-names>IB</given-names></name>. <article-title>Predictors of mortality in Staphylococcus aureus Bacteremia</article-title>. <source>Clin Microbiol Rev</source>. <year>2012</year>;<volume>25</volume>: <fpage>362</fpage>&#8211;<lpage>386</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/CMR.05022-11</pub-id><pub-id pub-id-type="pmid">22491776</pub-id><pub-id pub-id-type="pmcid">PMC3346297</pub-id></mixed-citation></ref><ref id="pone.0298612.ref017"><label>17</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hadano</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kakuma</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Matsumoto</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ishibashi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Isoda</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yasunaga</surname><given-names>H</given-names></name>. <article-title>Reduction of 30-day death rates from Staphylococcus aureus bacteremia by mandatory infectious diseases consultation: Comparative study interventions with and without an infectious disease specialist</article-title>. <source>Int J Infect Dis</source>. <year>2021</year>;<volume>103</volume>: <fpage>308</fpage>&#8211;<lpage>315</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ijid.2020.11.199</pub-id><pub-id pub-id-type="pmid">33278619</pub-id></mixed-citation></ref><ref id="pone.0298612.ref018"><label>18</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fowler</surname><given-names>VG</given-names></name>, <name name-style="western"><surname>Miro</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Hoen</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Cabell</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Abrutyn</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Rubinstein</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Staphylococcus aureus Endocarditis: a Consequence of Medical Progress</article-title>. <source>JAMA</source>. <year>2005</year>;<volume>293</volume>: <fpage>3012</fpage>&#8211;<lpage>3021</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.293.24.3012</pub-id><pub-id pub-id-type="pmid">15972563</pub-id></mixed-citation></ref><ref id="pone.0298612.ref019"><label>19</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Turnidge</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Kotsanas</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Munckhof</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bennett</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Nimmo</surname><given-names>GR</given-names></name>, <etal>et al</etal>. <article-title>Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand</article-title>. <source>Med J Aust</source>. <year>2009</year>;<volume>191</volume>: <fpage>368</fpage>&#8211;<lpage>373</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5694/j.1326-5377.2009.tb02841.x</pub-id><pub-id pub-id-type="pmid">19807625</pub-id></mixed-citation></ref><ref id="pone.0298612.ref020"><label>20</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Goto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Schweizer</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Livorsi</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Perencevich</surname><given-names>EN</given-names></name>, <name name-style="western"><surname>Richardson</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Association of Infectious Diseases Consultation With Long-term Postdischarge Outcomes Among Patients With Staphylococcus aureus Bacteremia</article-title>. <source>JAMA Network Open</source>. <year>2020</year>;<volume>3</volume>: <fpage>e1921048</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.21048</pub-id><pub-id pub-id-type="pmid">32049296</pub-id></mixed-citation></ref><ref id="pone.0298612.ref021"><label>21</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Saunderson</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Gouliouris</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nickerson</surname><given-names>EK</given-names></name>, <name name-style="western"><surname>Cartwright</surname><given-names>EJP</given-names></name>, <name name-style="western"><surname>Kidney</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Aliyu</surname><given-names>SH</given-names></name>, <etal>et al</etal>. <article-title>Impact of routine bedside infectious disease consultation on clinical management and outcome of Staphylococcus aureus bacteraemia in adults</article-title>. <source>Clin Microbiol Infect</source>. <year>2015</year>;<volume>21</volume>: <fpage>779</fpage>&#8211;<lpage>785</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cmi.2015.05.026</pub-id><pub-id pub-id-type="pmid">26033668</pub-id><pub-id pub-id-type="pmcid">PMC4509716</pub-id></mixed-citation></ref><ref id="pone.0298612.ref022"><label>22</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Martin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Brooks</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Main</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mertz</surname><given-names>D</given-names></name>. <article-title>Management and outcomes in patients with Staphylococcus aureus bacteremia after implementation of mandatory infectious diseases consult: a before/after study</article-title>. <source>BMC Infectious Diseases</source>. <year>2015</year>;<volume>15</volume>: <fpage>568</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12879-015-1296-y</pub-id><pub-id pub-id-type="pmid">26666459</pub-id><pub-id pub-id-type="pmcid">PMC4678701</pub-id></mixed-citation></ref><ref id="pone.0298612.ref023"><label>23</label><mixed-citation publication-type="journal"><name name-style="western"><surname>McCabe</surname><given-names>WR</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>G</given-names></name>. <article-title>Gram-Negative Bacteremia: I. Etiology and Ecology</article-title>. <source>Arch Intern Med</source>. <year>1962</year>;<volume>110</volume>: <fpage>847</fpage>&#8211;<lpage>855</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/ARCHINTE.1962.03620240029006</pub-id></mixed-citation></ref><ref id="pone.0298612.ref024"><label>24</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Sexton</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Mick</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Nettles</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fowler</surname><given-names>VG</given-names></name>, <name name-style="western"><surname>Ryan</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis</article-title>. <source>Clin Infect Dis</source>. <year>2000</year>;<volume>30</volume>: <fpage>633</fpage>&#8211;<lpage>638</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1086/313753</pub-id><pub-id pub-id-type="pmid">10770721</pub-id></mixed-citation></ref><ref id="pone.0298612.ref025"><label>25</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Levy</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Fink</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Marshall</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Abraham</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Angus</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Cook</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference</article-title>. <source>Crit Care Med</source>. <year>2003</year>;<volume>31</volume>: <fpage>1250</fpage>&#8211;<lpage>1256</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/01.CCM.0000050454.01978.3B</pub-id><pub-id pub-id-type="pmid">12682500</pub-id></mixed-citation></ref><ref id="pone.0298612.ref026"><label>26</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Forsblom</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ruotsalainen</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ollgren</surname><given-names>J</given-names></name>, <name name-style="western"><surname>J&#228;rvinen</surname><given-names>A</given-names></name>. <article-title>Telephone consultation cannot replace bedside infectious disease consultation in the management of Staphylococcus aureus Bacteremia</article-title>. <source>Clin Infect Dis</source>. <year>2013</year>;<volume>56</volume>: <fpage>527</fpage>&#8211;<lpage>535</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/cid/cis889</pub-id><pub-id pub-id-type="pmid">23087397</pub-id></mixed-citation></ref><ref id="pone.0298612.ref027"><label>27</label><mixed-citation publication-type="other">World Health Organization(WHO). Lexicon of alcohol and drug terms. World Health Organization; 1994. Available: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apps.who.int/iris/handle/10665/39461" ext-link-type="uri">https://apps.who.int/iris/handle/10665/39461</ext-link></mixed-citation></ref><ref id="pone.0298612.ref028"><label>28</label><mixed-citation publication-type="other">World Health Organization(WHO). The ICD-10 classification of mental and behavioural disorders. Gen&#232;ve, Switzerland: World Health Organization; 1993.</mixed-citation></ref><ref id="pone.0298612.ref029"><label>29</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ruotsalainen</surname><given-names>E</given-names></name>, <name name-style="western"><surname>J&#228;rvinen</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Koivula</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Kauma</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Rintala</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lumio</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients</article-title>. <source>J Intern Med</source>. <year>2006</year>;<volume>259</volume>: <fpage>179</fpage>&#8211;<lpage>190</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1365-2796.2005.01598.x</pub-id><pub-id pub-id-type="pmid">16420547</pub-id></mixed-citation></ref><ref id="pone.0298612.ref030"><label>30</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kamath</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>WR</given-names></name>, <collab>Advanced Liver Disease Study Group</collab>. <article-title>The model for end-stage liver disease (MELD)</article-title>. <source>Hepatology</source>. <year>2007</year>;<volume>45</volume>: <fpage>797</fpage>&#8211;<lpage>805</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/hep.21563</pub-id><pub-id pub-id-type="pmid">17326206</pub-id></mixed-citation></ref><ref id="pone.0298612.ref031"><label>31</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Maddrey</surname><given-names>WC</given-names></name>, <name name-style="western"><surname>Boitnott</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Bedine</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Weber</surname><given-names>FL</given-names></name>, <name name-style="western"><surname>Mezey</surname><given-names>E</given-names></name>, <name name-style="western"><surname>White</surname><given-names>RI</given-names></name>. <article-title>Corticosteroid therapy of alcoholic hepatitis</article-title>. <source>Gastroenterology</source>. <year>1978</year>;<volume>75</volume>: <fpage>193</fpage>&#8211;<lpage>199</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0016-5085(78)90401-8</pub-id><pub-id pub-id-type="pmid">352788</pub-id></mixed-citation></ref><ref id="pone.0298612.ref032"><label>32</label><mixed-citation publication-type="journal"><name name-style="western"><surname>de Roux</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cavalcanti</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Marcos</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Garcia</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ewig</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mensa</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia</article-title>. <source>Chest</source>. <year>2006</year>;<volume>129</volume>: <fpage>1219</fpage>&#8211;<lpage>1225</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1378/chest.129.5.1219</pub-id><pub-id pub-id-type="pmid">16685012</pub-id></mixed-citation></ref><ref id="pone.0298612.ref033"><label>33</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Laupland</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Ross</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gregson</surname><given-names>DB</given-names></name>. <article-title>Staphylococcus aureus Bloodstream Infections: Risk Factors, Outcomes, and the Influence of Methicillin Resistance in Calgary, Canada, 2000&#8211;2006</article-title>. <source>The Journal of Infectious Diseases</source>. <year>2008</year>;<volume>198</volume>: <fpage>336</fpage>&#8211;<lpage>343</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1086/589717</pub-id><pub-id pub-id-type="pmid">18522502</pub-id></mixed-citation></ref><ref id="pone.0298612.ref034"><label>34</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Oleski</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mota</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Cox</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Sareen</surname><given-names>J</given-names></name>. <article-title>Perceived need for care, help seeking, and perceived barriers to care for alcohol use disorders in a national sample</article-title>. <source>Psychiatr Serv</source>. <year>2010</year>;<volume>61</volume>: <fpage>1223</fpage>&#8211;<lpage>1231</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1176/ps.2010.61.12.1223</pub-id><pub-id pub-id-type="pmid">21123407</pub-id></mixed-citation></ref><ref id="pone.0298612.ref035"><label>35</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Matsuzaki</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vu</surname><given-names>QM</given-names></name>, <name name-style="western"><surname>Gwadz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Delaney</surname><given-names>JAC</given-names></name>, <name name-style="western"><surname>Kuo</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Trejo</surname><given-names>MEP</given-names></name>, <etal>et al</etal>. <article-title>Perceived access and barriers to care among illicit drug users and hazardous drinkers: findings from the Seek, Test, Treat, and Retain data harmonization initiative (STTR)</article-title>. <source>BMC Public Health</source>. <year>2018</year>;<volume>18</volume>: <fpage>366</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12889-018-5291-2</pub-id><pub-id pub-id-type="pmid">29554894</pub-id><pub-id pub-id-type="pmcid">PMC5859651</pub-id></mixed-citation></ref><ref id="pone.0298612.ref036"><label>36</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rieg</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Peyerl-Hoffmann</surname><given-names>G</given-names></name>, <name name-style="western"><surname>de With</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Theilacker</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wagner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>H&#252;bner</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Mortality of S. aureus bacteremia and infectious diseases specialist consultation&#8212;a study of 521 patients in Germany</article-title>. <source>J Infect</source>. <year>2009</year>;<volume>59</volume>: <fpage>232</fpage>&#8211;<lpage>239</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jinf.2009.07.015</pub-id><pub-id pub-id-type="pmid">19654021</pub-id></mixed-citation></ref><ref id="pone.0298612.ref037"><label>37</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Arokszallasi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Balogh</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Csiba</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fekete</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Fekete</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Olah</surname><given-names>L</given-names></name>. <article-title>Acute alcohol intoxication may cause delay in stroke treatment&#8211;case reports</article-title>. <source>BMC Neurology</source>. <year>2019</year>;<volume>19</volume>: <fpage>14</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12883-019-1241-6</pub-id><pub-id pub-id-type="pmid">30696413</pub-id><pub-id pub-id-type="pmcid">PMC6350361</pub-id></mixed-citation></ref><ref id="pone.0298612.ref038"><label>38</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Afshar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Richards</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mann</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Cross</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>GB</given-names></name>, <name name-style="western"><surname>Netzer</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Acute immunomodulatory effects of binge alcohol ingestion</article-title>. <source>Alcohol</source>. <year>2015</year>;<volume>49</volume>: <fpage>57</fpage>&#8211;<lpage>64</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.alcohol.2014.10.002</pub-id><pub-id pub-id-type="pmid">25572859</pub-id><pub-id pub-id-type="pmcid">PMC4314366</pub-id></mixed-citation></ref><ref id="pone.0298612.ref039"><label>39</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Foldi</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Tornai</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tornai</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sipeki</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Vitalis</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Tornai</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Lectin-complement pathway molecules are decreased in patients with cirrhosis and constitute the risk of bacterial infections</article-title>. <source>Liver Int</source>. <year>2017</year>;<volume>37</volume>: <fpage>1023</fpage>&#8211;<lpage>1031</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/liv.13368</pub-id><pub-id pub-id-type="pmid">28109038</pub-id></mixed-citation></ref><ref id="pone.0298612.ref040"><label>40</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Psaty</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Koepsell</surname><given-names>TD</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Weiss</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Siscovick</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Rosendaal</surname><given-names>FR</given-names></name>, <etal>et al</etal>. <article-title>Assessment and control for confounding by indication in observational studies</article-title>. <source>J Am Geriatr Soc</source>. <year>1999</year>;<volume>47</volume>: <fpage>749</fpage>&#8211;<lpage>754</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1532-5415.1999.tb01603.x</pub-id><pub-id pub-id-type="pmid">10366179</pub-id></mixed-citation></ref><ref id="pone.0298612.ref041"><label>41</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Huang</surname><given-names>H-K</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>H-Y</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>Y-C</given-names></name>. <article-title>Comparing the Prognosis of Patient with Alcohol and Nonalcohol-Associated Cirrhosis with Bacteremia</article-title>. <source>Alcohol and Alcoholism</source>. <year>2020</year>;<volume>55</volume>: <fpage>512</fpage>&#8211;<lpage>517</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/alcalc/agaa057</pub-id><pub-id pub-id-type="pmid">32599621</pub-id></mixed-citation></ref><ref id="pone.0298612.ref042"><label>42</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Abraham</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Bamberger</surname><given-names>DM</given-names></name>. <article-title>Staphylococcus aureus Bacteremia: Contemporary Management</article-title>. <source>Mo Med</source>. <year>2020</year>;<volume>117</volume>: <fpage>341</fpage>&#8211;<lpage>345</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1086/598186</pub-id><pub-id pub-id-type="pmid">32848271</pub-id><pub-id pub-id-type="pmcid">PMC7431060</pub-id></mixed-citation></ref><ref id="pone.0298612.ref043"><label>43</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jensen</surname><given-names>AG</given-names></name>. <article-title>Importance of focus identification in the treatment of Staphylococcus aureus bacteraemia</article-title>. <source>J Hosp Infect</source>. <year>2002</year>;<volume>52</volume>: <fpage>29</fpage>&#8211;<lpage>36</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1053/jhin.2002.1270</pub-id><pub-id pub-id-type="pmid">12372323</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>